GoAI
Get started
TuHURA Biosciences, Inc. logo

TuHURA Biosciences, Inc.

HURA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.00

−$0.22 · -9.91%

Aug 21, 4:00 PM ET

HURA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

62

Gaining

Sentiment

51

Mixed

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
James A. Bianco
Listed since
Feb 22, 2013
Employees
22

Market position

Day range

Current $2.00

52-week range

Current $2.00

Open
$2.19
Previous close
$2.22
Volume
384.98K
0.66× average
Average volume
580.09K
Average daily volume
Market cap
127.37M USD
Beta
-0.01
Market reference 1
50-day average
$2.2759
-12.12% below average
200-day average
$1.8272
+9.45% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.35M USD
P/E (TTM)
-3.7×
P/B (TTM)
6.91×
P/S (TTM)
0×
EV / EBITDA
-1.14×
Earnings yield
-82.89%
Free cash flow yield
-76.39%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-143.61%
Return on assets
-109.90%
Return on invested capital
-145.65%

Financial health

Debt / equity
0.02×
Current ratio
0.78×
Altman Z-score
-4.55
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−31.8M USD-80.15%

Net income

−30.06M USD-38.64%
Income trends across reported periods−5.97M USD−15.36M USD−24.75M USD−34.14M USDOperating income, FY2021: −22.68M USDOperating income, FY2022: −14.8M USDOperating income, FY2023: −8.45M USDOperating income, FY2024: −17.65M USDOperating income, FY2025: −31.8M USDNet income, FY2021: −22.66M USDNet income, FY2022: −14.65M USDNet income, FY2023: −8.32M USDNet income, FY2024: −21.68M USDNet income, FY2025: −30.06M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −22.68M USD. Operating income FY2022 −14.8M USD. Operating income FY2023 −8.45M USD. Operating income FY2024 −17.65M USD. Operating income FY2025 −31.8M USD. Net income FY2021 −22.66M USD. Net income FY2022 −14.65M USD. Net income FY2023 −8.32M USD. Net income FY2024 −21.68M USD. Net income FY2025 −30.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold——55K USD60K USD60K USD
Gross profit——−55K USD−60K USD−60K USD
Research and development20.53M USD13.34M USD2.66M USD9.31M USD15.17M USD
Selling, general, and administrative7.58M USD3.87M USD5.73M USD5.43M USD7.45M USD
Operating expenses31.8M USD17.65M USD8.4M USD14.74M USD22.62M USD
Interest income136.23K USD361.63K USD89.67K USD57.35K USD—
Interest expense625.28K USD4.14M USD18.69K USD—629.29K USD
Depreciation and amortization71.27K USD116.71K USD55K USD60K USD60K USD
Operating income−31.8M USD−17.65M USD−8.45M USD−14.8M USD−22.68M USD
Net income−30.06M USD−21.68M USD−8.32M USD−14.65M USD−22.66M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
CitizensmaintainMarket Outperform
Maxim GroupmaintainBuy

HURA news

seekingalpha.com

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

Read source
marketbeat.com

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell…

Read source
prnewswire.com

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer…

Read source
prnewswire.com

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer…

Read source
prnewswire.com

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML)…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 18, 2024

1:35

Stock split

Effective Nov 14, 2022

1:50

Stock split

Effective May 8, 2019

1:10

Stock split

Effective May 23, 2016

1:4

HURA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HURA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.78M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.04M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
383.86K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research HURA

research.disclaimer